title: Tc-99m MIBI to evaluate children with Ewing's sarcoma.
abstract: OBJECTIVE
  Tc-99m MIBI has been used increasingly to evaluate benign and malignant tumors because of its tumor-seeking properties and ability to provide an imaging assessment of multiple-drug resistance. This study investigated the clinical utility of Tc-99m MIBI in the management of Ewing's sarcoma in children.
  
  
  METHODS
  Thirteen Tc-99m MIBI studies in nine (six male, three female) patients ages 6.5 to 20 years (mean, 13.4 years) with Ewing's sarcoma were reviewed. All patients had imaging studies at diagnosis, and four had follow-up studies during or after therapy. Scintigraphy was evaluated for Tc-99m MIBI uptake within the tumor and in metastases, which other imaging modalities had shown to be present in four patients. Scintigraphic results were correlated with the clinical course in all patients and with tumor P-glycoprotein status in six patients.
  
  
  RESULTS
  Tc-99m MIBI accumulated in 6 of 9 primary tumors and did not accumulate in one recurrent tumor. No metastases showed Tc-99m MIBI uptake. The presence or absence of Tc-99m MIBI uptake at diagnosis or after therapy carried no prognostic significance. Tc-99m MIBI was present in the two tumors that were P-glycoprotein positive and in only one of four tumors that were P-glycoprotein negative.
  
  
  CONCLUSIONS
  Tc-99m MIBI imaging does not appear to be useful in Ewing's sarcoma.
authors.affiliation: Department of Nuclear Medicine, Rabin Medical Center, Petach-Tikva, Israel. barsev@isdn.net.il
authors.forename: Z
authors.initials: Z
authors.lastname: Bar-Sever
authors.forename: I J
authors.initials: IJ
authors.lastname: Cohen
authors.forename: L P
authors.initials: LP
authors.lastname: Connolly
authors.forename: G
authors.initials: G
authors.lastname: Horev
authors.forename: T
authors.initials: T
authors.lastname: Perri
authors.forename: T
authors.initials: T
authors.lastname: Treves
authors.forename: R
authors.initials: R
authors.lastname: Hardoff
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis; D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D002648:Child; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D005266:Femoral Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D010384:Pelvic Bones / Q000000981:diagnostic imaging; D011379:Prognosis; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012512:Sarcoma, Ewing / Q000000981:diagnostic imaging* / Q000473:pathology / Q000556:secondary / Q000628:therapy; D017256:Technetium Tc 99m Sestamibi
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi